Changes in US stocks | Sleep apnea drug developer Apnimed (APMD.US) opens in the US stock market, and the stock price rises by more than 11%

The Zhitong Finance App learned that on Friday, the American biotech company Apnimed (APMD.US), which focuses on treatment of obstructive sleep apnea, entered the US stock market, and its opening stock price rose more than 11% to 17.79 US dollars. The IPO price is $16. Apnimed is currently developing the oral medication Oxnimbi to treat obstructive sleep apnea. The company submitted a listing application to the US Food and Drug Administration (FDA) in April of this year. The regulatory approval period is expected to be about 10 months. If approved for marketing, Oxnimbi will be one of the few drugs approved to treat sleep apnea on the market after LLY.US (LLY.US) weight loss drug Zepbound, and will compete with it.